MedTrace Logo

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

NCT03144856 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-05-09

No results posted yet for this study

Summary

This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Apatinib

Apatinib 500mg, po, qd, every 4 weeks.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Rui-Hua Xu, MD, PhD · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-22
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03144856 on ClinicalTrials.gov